Metalytics Debuts World’s Most Advanced Metabolic Flux Analysis Offering, CoreMFA® – PR Newswire (press release)
|
Metalytics Debuts World’s Most Advanced Metabolic Flux Analysis Offering, CoreMFA®
PR Newswire (press release) The ultimate goal of metabolic engineering–the practice of optimizing the conversion of these raw materials into the necessary molecules, is high-yield production of valuable substances on an industrial scale in a cost-effective manner. With CoreMFA … |
Genetic Literacy Project |
Podcast: Geneticist George Church on the future of synthetic biology
Genetic Literacy Project George Church’s Harvard lab is one of the most celebrated fonts of innovation in the world of life sciences. George’s earliest work on the Human Genome Project arguably pre-dated the actual start of that project. … Much of George’s most recent and … Growth Opportunities in the Synthetic Biology Market, Forecast to 2024Pharmaceuticals News |
MIT Technology Review |
CRISPR trials are about to begin in people—but we still don’t know how well it works in monkeys
MIT Technology Review Some of the first CRISPR experiments in monkeys involve blood disorders like sickle-cell disease and beta thalassemia. CRISPR could be ideal for both diseases, scientists think, because each is caused by mutations in a single gene that makes hemoglobin … Why FDA’s proposed gene-editing regulations could stifle CRISPR research on food animalsGenetic Literacy Project Can the Gene-Editing Technology CRISPR Cure This Debilitating Brain Disease?Brinkwire (press release) |
STAT |
Biogen and the badly needed gene therapy acquisition that got away
STAT ast July, Biogen (BIIB 1) executives unveiled a new, more aggressive business development plan. Cash thrown off by the biotech’s maturing but still very profitable multiple sclerosis franchise would be redeployed to license or acquire new neuroscience … |
|
Biotech Analysis Central Pharma News: Novartis’s Gene Therapy Catch, AstraZeneca’s NASH Move, Clovis’s …
Seeking Alpha The biggest reason for the deal was because of AveXis knowledge in gene therapy. In addition, AveXis’s main clinical candidate is AVXS-101 treats spinal muscular atrophy (SMA), which is a rare disease that affects the motor nerve cells in the spinal … |
Proactive Investors Australia |
Cynata Therapeutics granted another patent for its unique stem cell technology
Proactive Investors Australia Cynata Therapeutics Ltd (ASX:CYP) has been granted a further patent covering aspects of its proprietary Cymerus™ stem cell platform by the U.S. Patent and Trademark Office (USPTO). The patent covers certain proprietary methods relating to the platform … Cynara’s stem cell technology platform granted new US patentManufacturers’ Monthly |